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Introduction. There has been limited information reported on the use of hepatic arterial therapy in liver dominant hepatic
metastases arising from lung cancer. The aim of this study was to evaluate the safety and eﬃcacy of hepatic arterial therapy in
the treatment of liver dominant hepatic metastases arising from lung cancer. Methods. Thirteen patients underwent a total of 30
treatment sessions with Drug-Eluting Beads. Eight of the thirteen received only doxorubicin DEB (17 of the total treatments), and
fourpatientsreceivedIrinotecanDEB(7ofthetotaltreatments).Results.Theplannedpreproceduraldosagewasamedianof75mg
(range 19–200), with total hepatic dose exposure being a median of 150mg (range 0–458), with a technical success rate of 97%
in all 29 treatments. There were 4 adverse events related to treatment, but no evidence of hepatic insuﬃciency. Overall 6-month
and 12-month response rates were 50%. After a median followup of 24 months, the median overall survival in this cohort was 14
months (range 7–48 months). Conclusion. Drug-eluting beads loaded with doxorubicin (DEBDOX) or irinotecan (DEBIRI) can
be safely and eﬀectively used in treatment of patients with liver predominant metastatic disease from lung cancer.
1.Introduction
Lung cancer is the leading cause of cancer-related mortality
not only in the United States but also around the world [1].
The four major histological types of lung cancer are squa-
mous cell carcinoma (30% to 40% of lung cancers), adeno-
carcinoma (25% to 30%), nonsmall cell lung carcinoma (less
than 10%), and small cell lung carcinoma (15% to 20%).
T h e s ef o u rt y p e sa r es u b d i v i d e di n t on u m e r o u ss u b t y p e s
[2]. Approximately 85% of patients present with squamous
or adenocarcinoma deﬁned as nonsmall cell lung cancer
(NSCLC) and treatment may consist of surgery, radiation
therapy, chemotherapy, or a combination of these modalities
depending on tumor stage and the goals of therapy [3]. Dis-
tant metastases speak against treatment with curative intent.
The most frequent locations of distant metastases are brain,
liver, skeleton, lungs, and adrenals [4].
Since at the time of diagnosis 50% of NSCLC patients
present with stage IV disease, only palliative treatment can
be oﬀered [5]. The success of chemotherapy depends on ap-
propriate selection of the patients. General condition, age,
and comorbidities are decisive factors [6]. The combination
of platinum with a modern combination partner, which is
the optimal chemotherapy, leads to survival times of around
10 months. The chemotherapy not only lengthens life, but in
most patients also improves symptoms [7].
Transcatheter arterial embolization (TAE) and che-
moembolization (TACE) are increasingly used as regional
therapeutic modalities for the treatment of unresectable he-
patic malignancies [8]. In general, TAE and TACE have
been used when surgical resection and/or systemic therapy
have failed to produce an adequate response or when
conventional therapy has been known to be ineﬀective
[9]. There has been almost no information reported on2 Journal of Oncology
the use of TACE in hepatic metastases arising from lung
cancer.
Drug-eluting bead TACE is a drug delivery system that
combines the local embolization of vasculature with the
release of chemotherapy into adjacent tissue. Its administra-
tionissimilartothatofconventionalTACE,anditrepresents
a minimally invasive procedure performed by interventional
radiologists [10, 11]. The beads occlude vasculature, causing
embolization,andthechemotherapyisdeliveredlocally[12].
Early phase 1 and nonrandomized phase 2 studies have
conﬁrmed the ability of this device to deliver a local, con-
trolled, and sustained dose of doxorubicin to the tumors,
withminimalsystemicdoxorubicinexposure[13].Arecently
completed randomized Phase 2 study demonstrated that
these drug-eluting doxorubicin beads had superior response
rates when compared to conventional TACE in advanced
HCC and signiﬁcantly less overall adverse events, including
doxorubicin-related side eﬀects [14].
In this study, the aim was to review our experience
with drug eluting bead therapy in the multidisciplinary
management of patients with liver dominant metastatic lung
cancer to the liver.
2.MaterialsandMethods
An IRB-approved prospective multi-institutional treatment
registry was reviewed to ﬁnd patients with lung cancer meta-
static to the liver, from which 805 patients undergoing 1358
treatments (TACE) for primary or secondary cancers in the
liver were evaluated from January 2007 to Jan 2011. The
registry was designed to satisfy the strict criteria for critical
appraising of the quality of a registry study with (1) a well-
described patient population, (2) hypothesis generating and
answering questions, (3) high quality data, with good quality
control, (4) independent assessment of outcomes, (5) good
clinically relevant followup with minimal loss of patients,
and(6)comparablepatientevaluationacrossallinstitutional
participating [15]. Thirteen patients presenting with liver
dominant metastatic lung cancer to the liver were treated
with doxorubicin or irinotecan drug-eluting beads.
The inclusion criteria were the following patients were
included for therapy if they were 18 years of age, of any race
or sex, histologic and radiologic (deﬁned as a mass lesion
in the liver greater than 1cm in size) proof of metastatic
lung cancer to the liver by percutaneous biopsy, who
were able to give informed consent and were eligible for
treatment. Patients must have had an ECOG performance
status score of less than equal to 2 with a life expectancy
of greater than equal to 3 months, nonpregnant with an
acceptable contraceptive (deﬁned by the treating physi-
cian) in pre-menopausal women. Exclusion to therapy
was contraindication to angiographic and selective visceral
catheterization, signiﬁcant extrahepatic disease, representing
an eminent life-threatening outcome, greater than 75% of
hepatic parenchymal involvement, severe liver dysfunction
(deﬁned as presence of ascites or bilirubin >2.5mg/dL),
pregnancy, and severe cardiac comorbidities. Only patients
with liver dominant (deﬁned as greater than 50% of the
overalltotaldiseaseburdenasmeasuredonbaselinepre-DEB
treating cross-sectional scanning of the Chest-Abdomen-
Pelvis.) were considered for treatment.
Patients were followed for any treatment-related adverse
experiences for 30 days after each treatment and monitored
for survival for two years. Follow-up assessments included
a triphase CT scan of the liver within at least one-to-two
months from the treatment completion and then every
three months after for the ﬁrst year and every six months
after during the second year, with the evaluation of the
enhancementpatternofthetargetlesionandtumorresponse
rates measured according to modiﬁed RECIST criteria [16].
3. Image-GuidedInfusion Technique
Deﬁning the amount of liver disease was integral to deﬁning
both the number of treatments and the type of catheter
position and therapy that would be performed. For ﬁnite
numbers of lesions deﬁned as less than four lesions, a
treatment cycle was planned for a minimum of two dosing
schedules of at least 100mg of drug-eluting beads with
doxorubicin (DEBDOX) to 150mg of DEBDOX loaded in
two bead vials or 100mg of drug eluting beads Irinotecan
(DEBIRI).Beadsizesofeither100to300microns,300to500
microns, or 500 to 700 microns could be utilized (Figure 1).
Treatment intervals were planned for every four to eight
weeks. The interval can be extended if causing toxicity to the
liver. Based on the extent of liver involvement, two-to-three
treatment cycles are planned. A repeat scan is done every
three months from the initial ﬁrst treatment cycle to evaluate
response. A treatment cycle is deﬁned as treatment of all liver
disease. A treatment is hepatic arterial therapy to one-single
lobe, which could also be a treatment cycle if a patient has
only unilobar disease. Finite disease was deﬁned as less than
10totallesionsintheliver.Thedegreeofstasiswasdeﬁnedas
complete-total loss of arterial ﬂow to the treated segment or
lobe,near-completelossofintratumoralvascularityandnear
loss of arterial ﬂow to the treated segment or lobe, partial-
loss of intratumoral vascularity, and no stasis.
For diﬀusedisease(bilobarwith>25%liverinvolvement)
a plan of a minimum of four-dosing schedule again of 100
to 150mg (depending on the extent of tumor burden and
the extent of hepatic parenchyma reserve) are loaded into
two bead vials of the similar size as above. The plan includes
at least two treatments per lobe with every three-to-four
week dosing schedule. The toxicity eﬀect is followed, and the
treatmentintervalisdeterminedaccordingly.RepeatCTscan
three months from the ﬁrst dose to evaluate tumor response.
For example, if patients present with bilobar disease, they
would receive ﬁrst bead treatment to right lobe, then three
weeks after second bead treatment to left lobe, then three
weeksafterthirdbeadtreatmenttorightlobe,andthenagain
three weeks later to left lobe. The decision on bead size was
up to the treating discretion based on their initial experience
with particle size and the degree of stasis that was planned to
be delivered at the end of the treatment [17–19]. The reason
for lobar infusion is based on the desire for drug delivery
and less on inducing stasis in patients with multifocal
lobar disease that is not amenable to superselective delivery
[20]. Additional embolic material is not usually followedJournal of Oncology 3
Patient with liver-predominant metastases from lung cancer
Yes No
Unilobar disease Bilobar disease
Selective and then lobar DEBDOX  Lobar DEBDOX in most affected lobe 
Contralateral lobe  DEBDOX
DEBDOX ﬁrst lobe
DEBDOX contralateral lobe  
Extrahepatic progression?
No                                                  Yes
Repeat treatment whenever residual tumour Other treatment options Imaging f-u
DEBDOX algorithm-hepatic lung metastases∗
150 mg doxorubicin in two 100–300 µm vial 150 mg doxorubicin in two 100–300 µm vial
150 mg doxorubicin in two 100–300 µm vial
150 mg doxorubicin in two 100–300 µm vial
Selective and then lobar DEBDOX 
150 mg doxorubicin in two 100–300 µm vial 150 mg doxorubicin in two 100–300 µm vial
4 wks
2 wks
2 wks
2 wks
3-month tumour response, thenevery 3-4 months for 1 year, then every 6 months for second year
Tumour response <80% Tumour response <80%
∗ This is a treatment guideline, dosages and size of beads may change based on the health of patient, health of liver
 parenchyma, size and location of tumors in the liver, and if the patient is on concurrent chemotherapy
Figure 1: Potential pretreatment DEBDOX treatment algorithm for treating liver dominant metastatic lung cancer. The timing of repeat
dosing and the dose utilized may have to be modiﬁed based on angiographic ﬁndings, patient tolerance, and patient toxicity.
after appropriate treatment but was up to the physician’s
discretion. Technical success was deﬁned as the ability to
deliver at least 75% of the preplanned procedural dose.
All bead therapies were performed with the DC/LC bead
microsphere (drug eluting bead (DEB); http://www.biocom-
patibles.com/ , Biocompatibles UK, Surrey, UK). The saline
suspension in the DC/LC bead microsphere was removed,
andthebeadsweremixedwithdoxorubicinsolutionatadose
of 75mg per 2mL at least four hours before the procedure
depending on the dose that was planned to be delivered.
3.1. Patient and Tumor Characteristics. Thirteen patients
underwent a total of 29 treatment sessions with DEBs.
Eight of the thirteen received only doxorubicin DEBs (17 of
the total treatments), and four patients received Irinotecan
DEBs (7 of the total treatments), (Table 1). There were 7
males (54%) and 6 females (46%) in this study, with a
median age of 68 years (range 43–72). Past medical histories
were signiﬁcant for prior cardiac disease in three patients,
underlying diabetes in three patients (one insulin dependent
and two noninsulin dependent), and prior alcohol abuse in
two patients as well as tobacco smoking in nine patients. Two
patients had vascular disease, seven had pulmonary disease,
and eight were hypertensive. Prior surgical histories included
prior cholecystectomy in four patients. The Karnofsky
performance scale was used to assess the pretreatment health
of the patients, and they all ranged (70–100) with a median
of 90%.
4. Results
The extent of liver involvement was <25% (n = 6), 26–50%
(n = 6), and 51–75% liver involvement in one patient. The
median number of target lesions was 4 (range 1–20). The4 Journal of Oncology
Table 1: Clinical characteristics in 13 lung metastatic patients
treated with LC beads.
Characteristics N = 13
Age (years) (median, range) 68 (43–72)
Gender
Male 7 (54%)
Female 6 (46%)
Past medical history
Cardiac 3 (23%)
Vascular 2 (15%)
Pulmonary 7 (54%)
Diabetes 3 (23%)
Insulin 1 (33%)
NonInsulin 2 (67%)
Alcohol 2 (15%)
Tobacco 9 (69%)
Median packs 60 (40–300)
Hypertension 8 (62%)
Prior cholecystectomy 4 (31%)
Karnofsky performance scale 90% (70–100)
Extent of liver lesions
Distinct number 11 (85%)
Numerous 2 (15%)
Liver involvement
<25% 6 (46%)
26–50% 6 (46%)
51–75% 1 (8%)
Number liver tumors (median, range) 4 (1–20)
1 18%
29 %
≥3 73%
Sum of target lesion(s) size (median, range) 12.7cm (2.5–21.8)
Lesion location
S e g2 – 4 1( 8 % )
S e g4 – 8 3( 2 3 % )
S e g5 – 8 2( 1 5 % )
Other 7 (54%)
total target lesion size (sum of a maximum of ﬁve lesions)
was 12.7cm (range 2.5–21.8cm).
4.1. Treatment. Thirteen patients underwent a total of 29
total bead courses of either DEBDOX or DEBIRI, with the
median number of treatments per patient being 2 (range 1–
5).Theplannedpreproceduraldosagewasamedianof75mg
(range 19–200), with total hepatic dose exposure being a
medianof150mg(range0–458),withatechnicalsuccessrate
of 97% in all 30 treatments. The most common bead size was
100–300 micron beads in 23 patients (23 vials total), 300–
500 micron beads in 5 patients (3.5 vials total), and 500–700
micron beads in 1 patient (1 vial total) (Table 2).
The degree of ﬂow occlusion in the 29 bead courses
included no stasis in 5 courses (17%), partial stasis in
Table 2: Bead catheter infusion outcomes.
N = 30 total treatments
Number of bead courses Median 2 (range 1–5)
Technical success 97%
Dosage delivered (median, range) 75mg (19–200)
Total hepatic dose exposure 150 (0–458)
1 150 (0–200)
2 150 (79–190)
3 325
>3 458
Bead Size Utilized
100–300 24
300–500 5
500–700 1
Complications 14%
Extrahepatic infusion 0
Hematologic changes
WBC −1.9 (−9994.4–9991.8)
HGB 0.1 (−9989.1–9987.5)
Bilirubin 0 (−9998.7–9998.8)
Table 3: Bead infusion-related morbidity.
Side eﬀect (N = 4) All grades Severe grade∗
Confusion 1 —
Dehydration — 1
Angina — 1
Hypotension 1 —
∗Deﬁned as Grade 3 or higher.
7courses (24%), near stasis in 6 courses (21%), and complete
stasis in 11 courses (38%).
4.2. Patient Tolerance, Morbidity, and Mortality. During the
29 treatments, four adverse events occurred (14%), with one
patient developing dehydration and confusion, grades 3 and
2 adverse events, respectively, both of which possibly related
to systemic chemotherapy eﬀect. One patient developed
angina,agrade3adverseeventthatrevolved.Anotherpatient
developed hypotension, a grade 2 adverse event that quickly
resolved (Table 3).
4.3. Follow-Up and Tumor Response. Response rates for all
patients were recorded at 3, 6, 9, 12, and 18 months.
ResponseratewasevaluatedusingmodiﬁedRECIST.Atthree
months, overall response was 54% with disease control of
70%, with one patient (8%) having a complete response, six
patients (46%) having a partial response, stable disease in
two patients (15%), and progressive disease in four patients
(31%). Location of progression was outside the liver in
the lung and bone in separate patients. Two patients died
of disease, and one died of other cause at three months.
Progression of disease was seen in two patients at 6 months,
and three died of disease at 6 months. Progression of disease
was seen in the liver in 1 patient with the remaining patientsJournal of Oncology 5
Table 4: Response rates∗ for all 13 patients evaluated.
Response 3mon N = 13 6mon N = 10 9mon N = 81 2 m o n N = 61 8 m o n N = 6
Complete response 1 1 1 2 1
Partial response 6 1 1 1 1
Stable disease 2 3 3 3 3
Progression of disease 4 2 1 0 0
Not Reached time point
D O D 2 320 1
D O C 1 000 0
DOD: dead of disease; DOC: dead of complication.
∗Response rates measured using modiﬁed RECIST criteria.
treated having progression to the bone, lymph nodes, or
primary tumor. At 9-month followup, the response rate was
20% with disease control of 50% with 2 patients achieving
overall response (1 patient CR and 1 patient PD). At the ﬁnal
follow-up time of 18 months, response rate was 40% with
one patient with CR, one patient with PR (Table 4). After a
median followup of 24 months, the median overall survival
in this cohort was 14 months (range 7–48 months).
5. Discussion
Liver metastasis from lung cancer is regarded as stage IV
diseasewhereonlypalliativetreatmentcanbeoﬀered.Chem-
otherapy is beneﬁcial for palliation in patients with locally
advanced and metastatic disease [21]. There is no reported
data concerning transarterial chemotherapy for liver metas-
tasis originating from lung cancer.
Transarterial therapies take advantage of the dual blood
supply of the liver. Approximately 80% of the blood sup-
ply to hepatic metastases arrives via the hepatic artery,
whereas three fourths of the blood supply to normal hepatic
parenchyma are portal venous. Hence, cytotoxic agents that
are infused selectively into the hepatic artery preferentially
target tumor cells over normal hepatic tissue. Transarterial
chemoembolization (TACE) is a catheter-based technique
that combines both regional chemotherapy and emboliza-
tion to increase the dwell time of cytotoxic agents and induce
ischemia in the tumor. The use of drug-eluting microspheres
in a new variation of the TACE method is designed to
improve the precision of drug delivery [22]. In our study
drug-eluting beads (DC/LC beads) loaded with doxorubicin
or irinotecan were used in treatment of liver metastases
from lung cancer. Beads are composed of biocompatible
polymers such as polyvinyl alcohol (PVA) hydrogel that has
been sulphonated to enable the binding of chemotherapy
[23]. The beads occlude vasculature, causing embolization,
and the chemotherapy is delivered locally [12]. However,
drawbacksofthismethodoftreatmentincludehazardsofthe
procedure itself and those related to the drug-eluting beads
such as nausea, vomiting, transient hypertension, pain, liver
abscess, and up to mortality.
This treatment so far has been performed in 13 patients,
eight of which died of disease progression and one out of
complication. The treatment was found to be safe, without
any signiﬁcant adverse events during the treatment phase
of the therapy. Systemic progression to lung, bone, and
peritoneum was the most common sites where patients
failed. The remaining is still in the study, and most of
the target lesions are decreasing in size, showing signiﬁcant
improvements on the prognosis of the patients, with no
related serious adverse events. These locations of progression
demonstrate the need for combination therapy of both
systemic therapy and local hepatic arterial therapy given the
propensity for even liver-dominant metastatic lung cancer
to demonstrate signiﬁcant progression outside the liver.
This unpredictability of progression demonstrates that a
monotherapy will have limited overall disease control.
The current literature for systemic chemotherapy to treat
liver dominant hepatic metastasis to the liver is limited.
The main reason for this is that this is a unique subset of
patients that have not been evaluated or recorded in the
medical oncology literature. There is a current unmet need
ofdeﬁninghowmanypatientswithstageIVlungcancerhave
liver-dominant diseaseandthuscouldpossiblyderivebeneﬁt
fromlocalregionalhepaticarterialtherapy.Onecomparative
study on radiation therapy by Eble et al. evaluated the role of
palliative irradiation was in 55 patients with liver metastases
from colorectal (n = 35), breast (n = 10), and lung cancer
(n = 10). A mean dose of 23.8Gy was delivered, with daily
fractions of 1.5 (n = 30), 1.8 (n = 1), or 2Gy (n = 16)
[24]. Complete and near complete pain relief was obtained
in six (28.6%) and nine (42.9%) patients. Median survival
was 36.5 days for patients with lung cancer, 70.5 and 73 days
for patients with breast and colorectal cancer.
Thus in conclusion, this represents the ﬁrst ever report
of hepatic arterial therapy in the management of liver-
dominantmetastaticlungcancer.Wehavedemonstratedthat
drug-eluting beads loaded with Doxorubicin or Irinotecan
can be safely and eﬀectively used in treatment of patients
with liver-predominant metastatic disease from lung cancer.
This should be considered as an alternative or in com-
bination with systemic chemotherapy in selected patients,
yielding promising tumor response.
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